. | After stopping gefitinib or erlotinib
. | After restarting gefitinib or erlotinib
. | 3 wks after adding everolimus
. |
---|---|---|---|

Median change in tumor diameter | +9% | −1% | −8% |

Mean change in tumor diameter | +9% | 1% | −9% |

Range in change in tumor diameter | −13% to +29% | −14% to +23% | −34% to +15% |

Median change in tumor volume | +50% | −1% | −11% |

Mean change in tumor volume | +61% | −4% | −10% |

Range in change in tumor volume | −4% to +260% | −27% to 15% | −40% to +26% |

Median change in SUV_{max} | +18% | −4% | −18% |

Mean change in SUV_{max} | +23% | −11% | −11% |

Range in change in SUV_{max} | −17% to +87% | −45% to +62% | −39% to +82% |

. | After stopping gefitinib or erlotinib
. | After restarting gefitinib or erlotinib
. | 3 wks after adding everolimus
. |
---|---|---|---|

Median change in tumor diameter | +9% | −1% | −8% |

Mean change in tumor diameter | +9% | 1% | −9% |

Range in change in tumor diameter | −13% to +29% | −14% to +23% | −34% to +15% |

Median change in tumor volume | +50% | −1% | −11% |

Mean change in tumor volume | +61% | −4% | −10% |

Range in change in tumor volume | −4% to +260% | −27% to 15% | −40% to +26% |

Median change in SUV_{max} | +18% | −4% | −18% |

Mean change in SUV_{max} | +23% | −11% | −11% |

Range in change in SUV_{max} | −17% to +87% | −45% to +62% | −39% to +82% |

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.